This transfer of shares worth Rs 10 lakh is part of verticalization of business operations.

Aurobindo Pharma to transfer shares in subsidiary to Curateq Biologics

The EBITDA came in at Rs 1,002 crore in Q4FY23, which is three percent higher as against Rs 974.4 crore recorded in the year-ago period.

Aurobindo Pharma posts 12% slump in Q4 net profit at Rs 506 crore, revenue jumps 11%

Drugmaker Aurobindo Pharma reported consolidated net profit for the March quarter declined more than 12% to ₹505.9 crore.

Aurobindo Pharma Q4 net declines 12%, revenue rises over 11% to ₹6,472.96 crore

Aurobindo Pharma subsidiary Eugia Pharma Specialties has received the final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, single-dose vials.

Aurobindo Pharma arm copy of Pfizer’s drug gets U.S. FDA nod

The Aurobindo Pharma Foundation has offered ₹6 lakh aid to Uppada-based tennis player Penupothula Lakshmi Sai Subhash, for his further training

Pharma company lends support to tennis player

‘Four observations procedural in nature’

US. FDA issues Form 483 with four observations to Aurobindo Pharma

A total of 33,832 shares changed hands on the counter till time (IST).

Aurobindo Pharma shares fall 2.33% as Nifty gains

Zydus Lifesciences, in particular, has been scaling 52-week highs with momentum staying highly elevated. Also, Aurobindo Pharma shares have seen a steeper rise, with aggressive chart structures.

Escorts, Bank of India: Select midcap stocks are poised for up to 20% gains

Aurobindo Pharma Foundation (APF), the philanthropic and CSR arm of Aurobindo Pharma, has built a state-of-the-art oncology block for MNJ Institute of Oncology and State Cancer Institute, Hyderabad with ₹80 crore. The funding was an initiative under Corporate Social Responsibility (CSR) of the Hyder…

Aurobindo Pharma Foundation sets up oncology block at MNJ Institute with ₹80 cr

Aurobindo Pharma share price has potential to target ₹1,100-1,200 over the next couple of years

Technical Call: Aurobindo Pharma- BUY

The company also appointed Venkat Nageswar Chalasani as the Independent Director of Apitoria Pharma.

Aurobindo Pharma appoints Sanjay Chaturvedi as CEO of its subsidiary

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).